share_log

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Belite Bio 將參加 H.C. Wainwright 第二屆年度 BioConnect 投資者大會
GlobeNewswire ·  05/13 08:00

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference being held in New York, NY, on May 20, 2024. The Company will host a fireside chat at 3:30 pm ET.

聖地亞哥,2024年5月13日(環球新聞專線)——Belite Bio, Inc.(納斯達克股票代碼:BLTE)是一家臨床階段的生物製藥藥物開發公司,專注於推進針對醫療需求未得到滿足的退行性視網膜疾病的新療法。該公司今天宣佈,執行管理團隊將參加5月在紐約州紐約舉行的H.C. Wainwright第二屆年度BioConnect投資者大會 2024 年 20 日。該公司將在美國東部時間下午 3:30 舉辦爐邊談話。

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: The replay will be archived for 90 days following the presentation date.

可以在Belite Bio網站投資者關係部分的 “活動” 選項卡下訪問爐邊談話的網絡直播,網址爲:重播將在演示日期後的90天內存檔。

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at .

關於 Belite Bio
Belite Bio是一家臨床階段的生物製藥藥物開發公司,專注於推進針對嚴重未滿足醫療需求的退行性視網膜疾病的新療法,例如1型Stargardt病(STGD1)和晚期乾性年齡相關性黃斑變性(AMD)的地理萎縮(GA),以及特定的代謝性疾病。Belite的主要候選藥物Tinlarebant是一種旨在減少眼內毒素積累的口服療法,目前正在對青少年 STGD1 受試者進行三期研究(DRAGON)和一項2/3期研究(DRAGON II)以及一項針對GA受試者的3期研究(PHOENIX)進行評估。欲了解更多信息,請在推特、Instagram、領英、臉書上關注我們,或訪問我們的網站。

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com

媒體和投資者關係聯繫人:
詹妮弗·伍
ir@belitebio.com
朱莉·法倫
belite@argotpartners.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論